Hello! Welcome to ONTORES!

CN +86-21-68388652

Your shopping cart is empty.

According to the order.

Ordering Center

MHC-I tumor epitopes

Published: 2016-11-23


Background:The stimulation of the immune system using oncolytic adenoviruses (OAds) has attracted significant interest and several studies suggested that OAds immunogenicity might be important for their efficacy. Therefore, we developed a versatile and rapid system to adsorb tumor-specific major histocompatibility complex class I (MHC-I) peptides onto the viral surface to drive the immune response toward the tumor epitopes.

Results: The model epitope SIINFEKLwas coated on OAd (PeptiCRAd). The SIINFEKL-targeting PeptiCRAd achieves a superior antitumor efficacy and increases the percentage of antitumor CD8+ T cells and mature epitope-specific dendritic cells in vivo. PeptiCRAds loaded with clinically relevant tumor epitopes derived from tyrosinase-related protein 2 (TRP-2) and human gp100 could reduce the growth of primary-treated tumors and secondary-untreated melanomas, promoting the expansion of antigen-specific T-cell populations. Finally, anti-tumor efficacy of PeptiCRAd was demonstrated in humanized mice bearing human melanomas.